Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18970024 | HEPATITIS E VIRUS-LIKE PARTICLES (VLPS) DERIVED FROM CONSENSUS SEQUENCES | December 2024 | December 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18010885 | CORONAVIRUS PSEUDOVIRUS PACKAGING SYSTEM, PACKAGING METHOD THEREFOR, AND APPLICATION OF CORONAVIRUS PSEUDOVIRUS IN EVALUATING DISINFECTION EFFICACY | June 2023 | December 2025 | Allow | 36 | 0 | 0 | No | No |
| 18252498 | ARTIFICIAL EXPRESSION CONSTRUCTS FOR MODULATING GENE EXPRESSION IN CHANDELIER CELLS | May 2023 | February 2026 | Allow | 33 | 0 | 1 | No | No |
| 18030730 | THERAPEUTIC ADENO-ASSOCIATED VIRUS DELIVERY OF FUKUTIN RELATED PROTEIN (FKRP) FOR TREATING DYSTROGLYCANOPATHY. DISORDERS INCLUDING LIMB GIRDLE 21 (LGMD21) | April 2023 | January 2026 | Allow | 33 | 0 | 1 | No | No |
| 18021097 | LIPOSOME COMPLEX FOR CANCER TREATMENT, COMPRISING NOVEL CD47 BINDER AND POLYNUCLEOTIDE | February 2023 | October 2025 | Allow | 32 | 0 | 0 | No | No |
| 18064189 | METHOD FOR PRODUCING STEM CELLS AND METHOD FOR PRODUCING SOMATIC CELLS | December 2022 | January 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18051517 | Pre-conditioned mesenchymal stem cells and preparations and applications thereof | November 2022 | March 2025 | Abandon | 29 | 0 | 1 | No | No |
| 18050963 | DOPAMINERGIC NEURONS COMPRISING MUTATIONS AND METHODS OF USE THEREOF | October 2022 | January 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18050414 | METHODS FOR CULTURING CELLS EXPRESSING C-JUN | October 2022 | August 2025 | Abandon | 34 | 1 | 1 | No | No |
| 18045148 | HUMANIZED CHIMERAS FOR THE PROSPECTIVE ASSESSMENT OF CELL ADDITION AND REPLACEMENT THERAPIES | October 2022 | February 2026 | Allow | 40 | 3 | 1 | Yes | No |
| 17938607 | USE OF EXOSOMES DERIVED FROM MESENCHYMAL STEM CELLS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | October 2022 | March 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17916974 | ENGINEERED IMMUNE CELLS | October 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17948105 | MULTITRANSGENIC PIGS COMPRISING TEN GENETIC MODIFICATIONS FOR XENOTRANSPLANTATION | September 2022 | February 2026 | Allow | 40 | 2 | 1 | No | No |
| 17930510 | NOVEL DESIGN OF GUIDE RNA AND USES THEREOF | September 2022 | February 2026 | Abandon | 50 | 0 | 1 | No | No |
| 17909354 | AUTOMATED METHOD FOR PREPARING KERATINOCYTES | September 2022 | January 2026 | Allow | 40 | 1 | 0 | No | No |
| 17760264 | CRISPR-BASED FOXP3 GENE ENGINEERED T CELLS AND HEMATOPOIETIC STEM CELL PRECURSORS TO TREAT IPEX SYNDROME PATIENTS | August 2022 | October 2025 | Allow | 38 | 1 | 0 | No | No |
| 17788886 | CELL CULTURE SUBSTRATE AND MANUFACTURING METHOD THEREFOR | June 2022 | December 2025 | Allow | 42 | 1 | 0 | No | No |
| 17786433 | SMALL MOLECULE COMPOUNDS FOR AMPLIFYING HEMATOPOIETIC STEM CELLS, AND COMBINATION THEREOF | June 2022 | December 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17755294 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF TUMOR | April 2022 | November 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17770917 | METHODS OF PERFORMING RNA TEMPLATED GENOME EDITING | April 2022 | October 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17634766 | GENETICALLY ENGINEERED HUMAN FETAL LIVER NICHE AS PLATFORM FOR BIOMANUFACTURING OF HEMATOPOIETIC STEM CELLS | February 2022 | March 2026 | Allow | 49 | 2 | 1 | No | No |
| 17587911 | METHODS OF ISOLATION AND USE OF CD39 STROMAL STEM CELLS | January 2022 | March 2026 | Abandon | 49 | 2 | 0 | No | No |
| 17628793 | TRANSGENIC NON-HUMAN ANIMAL CAPABLE OF CONTROLLING EXPRESSION OF TRANSCRIPTION FACTOR RP58 | January 2022 | November 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17627440 | NUCLEIC ACID LOADED FLOWABLE HYDROGELS AND COMPOSITIONS, SYSTEMS AND METHODS RELATED THERETO | January 2022 | January 2026 | Allow | 48 | 1 | 0 | No | No |
| 17624257 | Thrombin Binding Circular Aptamer and Use Thereof | December 2021 | May 2025 | Allow | 41 | 1 | 0 | No | No |
| 17624196 | VECTOR COMPOSITIONS AND METHODS OF USING SAME FOR TREATMENT OF LYSOSOMAL STORAGE DISORDERS | December 2021 | July 2025 | Allow | 42 | 1 | 0 | No | No |
| 17624145 | COMPOSITIONS AND METHODS FOR GENE REPLACEMENT | December 2021 | February 2026 | Allow | 49 | 2 | 1 | No | No |
| 17623738 | CELL CULTURE SCAFFOLD, PRODUCTION METHOD THEREOF, SCAFFOLD PRODUCTION KIT, AND PRODUCTION METHOD OF CELL CULTURE PRODUCT | December 2021 | June 2025 | Abandon | 42 | 2 | 1 | Yes | No |
| 17623412 | HOST SYSTEMS COMPRISING INHIBITORS OF A GENE-EDITING PROTEIN FOR PRODUCTION OF VIRAL VECTORS | December 2021 | May 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17596746 | MODULAR PHAGE VECTOR PLATFORM FOR SONODYNAMIC THERAPY | December 2021 | January 2026 | Allow | 49 | 1 | 0 | No | No |
| 17414495 | PHARMACEUTICAL COMPOSITION COMPRISING CLONAL STEM CELLS FOR TREATING GRAFT-VERSUS-HOST DISEASE | December 2021 | May 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17617876 | ERYTHROCYTE REMOVAL DEVICE, MONONUCLEAR CELL COLLECTOR, CELL CULTURE DEVICE, CELL CULTURE SYSTEM, CELL CULTURE METHOD, AND MONONUCLEAR CELL COLLECTION METHOD | December 2021 | July 2025 | Allow | 43 | 1 | 1 | No | No |
| 17596187 | ANALYSIS OF MATERIALS FOR TISSUE DELIVERY | December 2021 | December 2025 | Abandon | 48 | 1 | 0 | No | No |
| 17608701 | Cardiomyocyte Compositions and Use Thereof | November 2021 | July 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17488702 | ENGINEERED REGULATORY T CELLS | September 2021 | March 2025 | Allow | 42 | 0 | 1 | No | No |
| 17335568 | GENETICALLY MODIFIED RAT MODELS FOR SEVERE COMBINED IMMUNODEFICIENCY (SCID) | June 2021 | December 2024 | Allow | 42 | 0 | 0 | No | No |
| 17203398 | NON-HUMAN ANIMALS EXPRESSING EXOGENOUS TERMINAL DEOXYNUCLEOTIDYLTRANSFERASE | March 2021 | January 2025 | Allow | 46 | 0 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner MCCORMICK, CATHERINE LYNN works in Art Unit 1638 and has examined 13 patent applications in our dataset. With an allowance rate of 61.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.
Examiner MCCORMICK, CATHERINE LYNN's allowance rate of 61.5% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MCCORMICK, CATHERINE LYNN receive 0.85 office actions before reaching final disposition. This places the examiner in the 6% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by MCCORMICK, CATHERINE LYNN is 43 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a -66.7% benefit to allowance rate for applications examined by MCCORMICK, CATHERINE LYNN. This interview benefit is in the 0% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 98% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.